Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback

Simply Wall St.01-16

AdvertisementProtagonist Therapeutics: Recent Move After Strong Multi‑Year Returns Protagonist Therapeutics (PTGX) has drawn fresh attention after a strong 1 year total return of about 132%, set ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603295154?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-16 08:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603295154","market":"nz","top_or_hot":-1,"title":"Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementProtagonist Therapeutics: Recent Move After Strong Multi‑Year Returns Protagonist Therapeutics (PTGX) has drawn fresh attention after a strong 1 year total return of about 132%, set ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-valuation-check-after-strong-m\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 08:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-valuation-check-after-strong-m><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementProtagonist Therapeutics: Recent Move After Strong Multi‑Year Returns Protagonist Therapeutics (PTGX) has drawn fresh attention after a strong 1 year total return of about 132%, set ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-valuation-check-after-strong-m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-valuation-check-after-strong-m","article_id":"2603295154","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-valuation-check-after-strong-m","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603295154","pubTimestamp":1768524209,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Protagonist Therapeutics: Recent Move After Strong Multi‑Year Returns\nProtagonist Therapeutics (PTGX) has drawn fresh attention after a strong 1 year total return of about 132%, set against more mixed shorter term moves, including a 7% decline over the past month.\nSee our latest analysis for Protagonist Therapeutics.\nAt a share price of $84.75, Protagonist Therapeutics has seen some momentum cool in the past month. Its 90 day share price return of 9.35% sits against a very large 3 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","PTGX":"Protagonist Therapeutics Inc"},"translate_title":"Protagonist Therapeutics(PTGX)在多年强劲回报和近期股价回调后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":1.5,"DCF":1},"content_text":"AdvertisementProtagonist Therapeutics: Recent Move After Strong Multi‑Year Returns Protagonist Therapeutics (PTGX) has drawn fresh attention after a strong 1 year total return of about 132%, set against more mixed shorter term moves, including a 7% decline over the past month. See our latest analysis for Protagonist Therapeutics. At a share price of $84.75, Protagonist Therapeutics has seen some momentum cool in the past month. Its 90 day share price return of 9.35% sits against a very large 3 year total shareholder return, which may indicate that recent moves reflect shifting views on trial progress, execution risk and what investors are willing to pay for that track record. If this kind of biotech story has your attention, it could be a good moment to scan for other healthcare stocks that fit your risk and return preferences. With Protagonist posting a very large 3 year total return, trading at $84.75 and sitting around 14% below one set of analyst targets, investors may ask whether there is still a buying opportunity or whether potential future developments are already reflected in the share price. Price-to-Earnings of 115.4x: Is it justified? On a P/E of 115.4x at a share price of $84.75, Protagonist Therapeutics trades at a much richer earnings multiple than many investors might expect for a company in the biotech space. The P/E ratio compares the current share price to earnings per share and is a quick way to see how much the market is paying for each dollar of earnings. For a research heavy biopharma group like Protagonist, a high P/E often reflects expectations about future earnings rather than the current profit base. Here, the market valuation sits far above several reference points. The company is described as expensive relative to an estimated fair P/E of 32.6x, which is a level the market could move toward if expectations cool. It is also flagged as expensive against the US Biotechs industry average P/E of 20.7x and a peer average of 23.9x, which are all much lower benchmarks than the current 115.4x. Explore the SWS fair ratio for Protagonist Therapeutics Result: Price-to-Earnings of 115.4x (OVERVALUED) However, that rich 115.4x P/E and reliance on successful trial outcomes for drugs like Rusfertide and Icotrokinra mean setbacks or delays could quickly challenge the current optimism. Find out about the key risks to this Protagonist Therapeutics narrative. Another View: DCF Points in a Very Different Direction While the 115.4x P/E suggests Protagonist Therapeutics looks expensive, our DCF model tells a very different story. With an estimated fair value of US$229.86 compared with the current US$84.75 share price, the stock is described as trading 63.1% below that fair value estimate. Which signal do you treat as more important, the earnings multiple or the cash flow view? Look into how the SWS DCF model arrives at its fair value. PTGX Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 867 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Protagonist Therapeutics Narrative If you look at the numbers and reach a different conclusion, or just prefer to test the assumptions yourself, you can build a custom view in minutes. Start with Do it your way. A great starting point for your Protagonist Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Interested in more stock ideas? If Protagonist has sharpened your curiosity, do not stop here. You could miss out on other stocks that better fit your goals and risk comfort.  Target potential mispricings by checking out these 867 undervalued stocks based on cash flows that align with your views on quality and price. Spot emerging themes in artificial intelligence by reviewing these 24 AI penny stocks that tie real business models to AI opportunities. Add growth potential with income by scanning these 12 dividend stocks with yields > 3% that combine yield with business fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603295154","isCrawlerRequest":true}